Manufactures complex generic injectable drugs for hospitals and pharma companies worldwide, majority-owned by China's Fosun Pharma.
Manufactures complex generic injectable drugs for hospitals and pharma companies worldwide, majority-owned by China's Fosun Pharma.
Makes sterile injectable drugs both for partner companies that sell them under their own labels and under its own filings, and most sales go to regulated markets, with the United States the largest. It widened its contract-manufacturing side by buying Cenexi, a French contract manufacturer.
In one line: India's Fresenius Kabi/Hikma of injectables.
Moat: narrow (regulatory licence, process know-how). US FDA-approved sterile injectable manufacturing facilities are costly and slow for rivals to replicate.
Headquarters: Hyderabad, India · Founded: 1978 · Employees: 4,332
Size Gland Pharma (GLAND.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $5.71B, the 197th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,230 on 18 Nov 2026.
Performance Over six months the shares gained 43.5%, against -8.4% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 21.9% over the last twelve months (peer median +11.3%); the operating margin is 20.9% (peer median 20.3%).
Valuation It trades at 39.3× forward earnings against a peer median of 22.6× (2nd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.3 points above its cost of capital (9.4% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹70.7B | ₹64.0B | ₹55.9B | ₹56.4B | ₹36.1B |
| Revenue growth | — | +15% | -1% | +56% | — |
| Gross profit | ₹22.5B | ₹16.3B | ₹12.6B | ₹13.8B | ₹11.0B |
| EBITDA | ₹19.2B | ₹16.6B | ₹12.8B | ₹13.4B | ₹10.3B |
| Net income | ₹12.4B | ₹10.3B | ₹6.99B | ₹7.72B | ₹7.81B |
| Free cash flow | n/a | ₹7.41B | ₹6.56B | ₹7.18B | ₹2.97B |
| Capital expenditure | n/a | ₹4.94B | ₹3.94B | ₹3.98B | ₹2.23B |
| Total debt | ₹2.51B | ₹2.84B | ₹3.14B | ₹3.72B | ₹44.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Gland Pharma GLAND.NS | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% |
| Hikma Pharmaceuticals HIK.L | $4.58B | +15% | +2% | 20% | 9.8× | 2.0% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Piramal Pharma PPLPHARMA.NS | $3.40B | +38% | +9% | 3% | 150.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GLAND.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.0% | +1.2% | 7th highest of 21 |
| 6-month return | +43.5% | -8.4% | 2nd highest of 20 |
| Distance from 52-week high | -5.8% | -25.4% | 2nd highest of 21 |
| Revenue growth (TTM) | +21.9% | +11.3% | 6th highest of 17 |
| Operating margin | 20.9% | 20.3% | 9th highest of 18 |
| Forward P/E | 39.3× | 22.6× | 2nd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 20.2% | 1.7% | 2nd most demanding of 14 |
| Growth delivered (Del g) | +13.3% | +13.9% | 7th lowest of 14 |
| Hurdle (Req g minus delivered) | +6.8 pp | -16.1 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | +5.3 pp | +2.1 pp | 6th highest of 17 |
| EV / EBITDA | 26.1× | 16.8× | 2nd most expensive of 11 |
| Net debt / EBITDA | -1.7× | 0.1× | 2nd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| RemeGen 9995.HK | Hong Kong | $6.07B | -28% | +293% | 61% | 6.3× | -6.8% | +57.9% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |